CRISPR pioneer Caribou Biosciences announced a restructuring on October 6: all clinical development paused, deep layoffs, and an investment bank hired to explore a sale or merger. For the biotech co-founded by Nobel laureate Jennifer Doudna, it is effectively the end of the road as a research company.
The company's announcement says its board approved the restructuring on October 2: the vispa-cel and CB-011 allogeneic CAR-T clinical programs are discontinued; major layoffs are expected to be substantially complete in the fourth quarter of 2026, alongside contract terminations, IP licensing arrangements and facility leases being wound down. CEO Rachel Haurwitz called it "an extremely difficult decision," stressing it does not reflect any loss of belief that the two therapies could benefit patients — the real reason, she said, is a worsening financing environment for allogeneic CAR-T: the company could not "responsibly raise the capital needed to advance the clinical programs."
Vispa-cel (formerly CB-010), for relapsed/refractory B-cell non-Hodgkin lymphoma, was the first allogeneic CAR-T with a PD-1 knockout in the clinic, pivotal-trial ready with the FDA aligned on a Phase 3 design, and held RMAT, fast-track and orphan-drug designations; the company had claimed safety and efficacy "comparable to autologous CAR-T." CB-011 targeted relapsed/refractory multiple myeloma. In March 2025 the company had already cut 32% of staff to preserve cash and killed its lupus program to go all-in on cancer — and now the cancer pipeline is gone too. The announcement says nothing about transition arrangements for patients already enrolled in trials.
As of June 30, 2026, the company held $113.8 million in cash, cash equivalents and marketable securities; restructuring charges are estimated at $15–19 million, per TipRanks citing SEC filings, mostly severance, healthcare and clinical wind-down costs. On the news, CRBU fell from a prior close of $1.135 to $0.65275 — a one-day plunge of about 42.5% — leaving a market cap of roughly $131 million, below the value of its cash. CFO Sriram Ryali will depart upon execution of any final strategic transaction.
The company has hired Wedbush Securities as exclusive financial advisor to explore a merger, acquisition, business combination or other strategic transaction involving its assets — with no timetable, and no further disclosure until the board approves something. Caribou was founded in 2011, among the first companies turning CRISPR gene editing into human medicines, and raised $304 million in its 2021 IPO.
Caribou's trouble is not unique. Allogeneic, off-the-shelf CAR-T has struggled to prove durable efficacy comparable to approved autologous, personalized CAR-T, and the whole field faces a financing drought. The fall of a CRISPR pioneer reads more as a footnote to the funding winter than as a failure of the technology.